【摘要】 食管癌是我国常见的消化道恶性肿瘤之一,多学科综合治疗疗效较单纯手术、放疗或化疗疗效有显著性提高,CROSS试验结果使新辅助放化疗成为以腺癌为主的西方国家可切除局部晚期食管癌的标准治疗手段。然而一些研究发现新辅助放化疗后临床疗效显著患者序贯手术与序贯放疗的总生存相似。全文就针对新辅助放化疗后疗效显著患者继续手术或非手术干预的若干问题进行了综述。更多还原

【Abstract】 Esophageal cancer is one of the most common malignancies in China. The outcome of multidisciplinary treatment modalities is significantly better compared with surgery,chemotherapy or radiotherapy alone. Since the chemoradiation therapy for oesophageal cancer followed by surgery study(CROSS),preoperative chemoradiotherapy(CRT) is considered as the standard care in Western countries where most of esophageal cancer cases are adenocarcinoma. Some trials had compared neoadjuvant CRT followed by surgery with definitive CRT,and found that patients who responded well to neoadjuvant chemotherapy or CRT showed a similar survival rate. In this article,the issues about choosing neoadjuvant CRT followed by surgery or definitive CRT with good respond after neoadjuvant chemoradiotherapy for esophageal carcinoma are reviewed.更多还原